Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib vs Imatinib in Chinese Patients with CML-CP
NCT01275196Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2011
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nilotinib in chronic myeloid leukemia (CML) (2 arms), sponsored by Novartis. Primary endpoint: Major Molecular Response at 12 months. Started Apr 2011; status: completed.
02
Drugs
nilotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01275196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01275196.